EE200200123A - Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine - Google Patents

Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine

Info

Publication number
EE200200123A
EE200200123A EEP200200123A EEP200200123A EE200200123A EE 200200123 A EE200200123 A EE 200200123A EE P200200123 A EEP200200123 A EE P200200123A EE P200200123 A EEP200200123 A EE P200200123A EE 200200123 A EE200200123 A EE 200200123A
Authority
EE
Estonia
Prior art keywords
tyrosine kinase
pharmaceutical composition
therapeutic use
inhibiting compound
kinase inhibiting
Prior art date
Application number
EEP200200123A
Other languages
English (en)
Inventor
T. Bilodeau Mark
W. Hungate Randall
Rodman Leonard
D. Hartman George
J. Manley Peter
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE200200123A publication Critical patent/EE200200123A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
EEP200200123A 1999-09-10 2000-09-06 Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine EE200200123A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15334899P 1999-09-10 1999-09-10
PCT/US2000/024432 WO2001017995A1 (en) 1999-09-10 2000-09-06 Tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EE200200123A true EE200200123A (et) 2003-08-15

Family

ID=22546828

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200123A EE200200123A (et) 1999-09-10 2000-09-06 Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine

Country Status (23)

Country Link
US (2) US6586424B2 (et)
EP (1) EP1218376B1 (et)
JP (2) JP3892296B2 (et)
KR (1) KR20020027635A (et)
CN (1) CN1390215A (et)
AT (1) ATE309241T1 (et)
AU (1) AU779908B2 (et)
BG (1) BG106465A (et)
BR (1) BR0013899A (et)
CA (1) CA2384101A1 (et)
CZ (1) CZ2002861A3 (et)
DE (1) DE60023926T2 (et)
EA (1) EA200200351A1 (et)
EE (1) EE200200123A (et)
ES (1) ES2250186T3 (et)
HU (1) HUP0202682A3 (et)
IL (1) IL148385A0 (et)
MX (1) MXPA02002559A (et)
NO (1) NO20021166L (et)
PL (1) PL355639A1 (et)
SK (1) SK4772002A3 (et)
WO (1) WO2001017995A1 (et)
ZA (1) ZA200201898B (et)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
SI1347971T1 (sl) * 2000-12-21 2006-06-30 Bristol Myers Squibb Co Tiazolilni inhibitorji tirozin kinaz Tec druzine
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
ATE318812T1 (de) 2000-12-21 2006-03-15 Bristol Myers Squibb Co Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2004536057A (ja) 2001-05-11 2004-12-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド ｐ３８インヒビターとして使用する２，５−二置換ピリジン、ピリミジン、ピリダジンおよび１，２，４−トリアジンの誘導体
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
JP2004535437A (ja) * 2001-06-22 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005511500A (ja) 2001-08-31 2005-04-28 ザ ロックフェラー ユニバーシティー 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ１ｂ媒介シグナル伝達の調節
WO2003027276A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
CA2483084A1 (en) 2002-05-02 2003-11-13 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2486183C (en) * 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
US20040023978A1 (en) * 2002-07-24 2004-02-05 Yu Ren Active salt forms with tyrosine kinase activity
US20040023981A1 (en) * 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
AU2002953255A0 (en) * 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US20060241122A1 (en) * 2003-05-30 2006-10-26 Lee Margaret S Combination therapy for the treatment of neoplasms
JP2007516196A (ja) * 2003-07-02 2007-06-21 ガラパゴス エヌブイ Ｒｈｏキナーゼ阻害剤としてのピラジン及びピラリジン誘導体
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
KR101206843B1 (ko) 2003-12-03 2012-11-30 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 튜불린 저해제
US7294640B2 (en) 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
DE602005011279D1 (de) * 2004-06-04 2009-01-08 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1813609B1 (en) * 2004-10-29 2013-06-19 Msd K.K. Novel aminopyridine derivatives having selective aurora-a inhibitory effect
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
RS52061B (en) 2005-02-04 2012-04-30 Astrazeneca Ab PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CA2608153C (en) 2005-05-24 2014-09-23 Laboratoires Serono S.A. Thiazole derivatives for use as p13k modulators
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
KR20140022114A (ko) 2005-06-06 2014-02-21 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2007016228A2 (en) * 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
ES2372540T3 (es) * 2005-11-01 2012-01-23 Array Biopharma, Inc. Activadores de glucocinasa.
US20070130203A1 (en) * 2005-12-07 2007-06-07 Ask Jeeves, Inc. Method and system to provide targeted advertising with search results
KR100728221B1 (ko) * 2005-12-08 2007-06-13 한국전자통신연구원 터보부호 ｏｆｄｍ 시스템용 반복적 잔류 주파수 위상 보정장치 및 그 방법
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CN101437816B (zh) 2006-03-24 2013-08-14 阿雷生物药品公司 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US8246966B2 (en) * 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
CA2669531A1 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
CA2672903C (en) 2006-12-20 2012-10-23 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
ES2522169T3 (es) * 2007-02-13 2014-11-13 Ab Science Forma polimorfa de derivado de 2-amino (nitroaril) tiazol
WO2008111441A1 (ja) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. 医薬組成物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
MX2010002772A (es) 2007-09-21 2010-03-31 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
SI2195312T1 (sl) 2007-10-09 2013-01-31 Merck Patent Gmbh Derivati piridina, uporabni kot aktivatorji glukokinaze
CN101952282A (zh) 2007-12-20 2011-01-19 诺瓦提斯公司 用作pi 3激酶抑制剂的噻唑衍生物
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EP2456790A1 (en) 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
JP5513620B2 (ja) 2009-08-31 2014-06-04 ポステック・アカデミー‐インダストリー・ファウンデーション 血管内皮細胞成長因子受容体の阻害によるＴｈ１７炎症疾患治療方法およびこのための薬学的組成物
JP5819307B2 (ja) 2009-10-20 2015-11-24 ネステク ソシエテ アノニム 発癌性融合タンパク質を検出するための近接媒介性アッセイ
KR100953511B1 (ko) * 2009-12-28 2010-04-21 (주)지노믹트리 건선 진단용 키트 및 칩
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2011344270A1 (en) 2010-12-17 2013-07-18 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP2675494B1 (en) 2011-02-17 2016-05-18 Nestec S.A. Apparatus and method for isolating leukocytes and tumor cells by filtration
UA112539C2 (uk) 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
RU2011122942A (ru) * 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
SG11201400518RA (en) 2011-09-12 2014-04-28 Sanofi Sa Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
SI2567958T1 (sl) 2011-09-12 2015-01-30 Sanofi Substituirani 2-(kroman-6-iloksi)-tiazoli in njihova uporaba kot farmacevtiki
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
DK2844282T3 (da) 2012-05-04 2019-07-15 Pfizer Prostata-associerede antigener og vaccine-baserede immunterapiregimener
KR20150015501A (ko) 2012-05-30 2015-02-10 니뽄 신야쿠 가부시키가이샤 방향족 복소환 유도체 및 의약
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9073936B2 (en) 2013-03-15 2015-07-07 Intra-Cellular Therapies, Inc. Organic compounds
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
CN103254184B (zh) * 2013-05-27 2015-03-18 湖南科技大学 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途
CN103319467B (zh) * 2013-06-15 2015-10-14 湖南科技大学 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途
RU2675516C2 (ru) 2013-08-02 2018-12-19 Пфайзер Инк. Anti-cxcr4 антитела и конъюгаты антитело-лекарство
PL226024B1 (pl) 2013-10-23 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Zastosowanie N-[2-[4-(4-metoksyfenylo)-1,3-tiazol-2-ilo]etylo]- -2-okso-2,5,6,7-tetrahydrocyklopenta[b] pirydyno-3-karboksyamidu
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
DK3177627T3 (da) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
US10059702B2 (en) 2014-09-08 2018-08-28 The Johns Hopkins University Inhibitors of LC3/ATG3 interaction and their use in the treatment of cancer
EP3725789B1 (en) 2014-09-17 2022-03-09 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
US10704104B2 (en) 2014-10-20 2020-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening a subject for a cancer
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
EP3319990A1 (en) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies having specificity to myosin 18a and uses thereof
ES2955775T3 (es) 2015-08-27 2023-12-07 Inst Nat Sante Rech Med Métodos para predecir el tiempo de supervivencia de pacientes que padecen cáncer de pulmón
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
EP3419999B1 (en) 2016-02-26 2021-08-04 (INSERM) Institut National de la Santé et de la Recherche Médicale Antibodies having specificity for btla and uses thereof
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
IL263224B2 (en) 2016-05-25 2024-03-01 Inst Nat Sante Rech Med Use of a HISTONE DEACETYLASE inhibitor and a population of activation-free pluripotent cells for cancer treatment
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
KR102646708B1 (ko) 2016-10-21 2024-03-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 반응을 촉진하는 방법
US20190345500A1 (en) 2016-11-14 2019-11-14 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
JP7171611B2 (ja) * 2017-04-21 2022-11-15 スティーブン・ホフマン 網膜症を治療するための組成物及び方法
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
WO2019072885A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
WO2019072888A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
WO2019101956A1 (en) 2017-11-24 2019-05-31 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for treating cancers
EP3720974A1 (en) 2017-12-07 2020-10-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Method for screening a subject for a cancer
CN107868040A (zh) * 2017-12-21 2018-04-03 苏州艾缇克药物化学有限公司 一种2‑氨基吡啶‑4‑甲酸甲酯的合成方法
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
EP3775206A1 (en) 2018-03-28 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
KR102245670B1 (ko) * 2018-04-03 2021-04-29 영남대학교 산학협력단 신규한 6-헤테로아릴아미노-2,4,5-트라이메틸피리딘-3-올 화합물, 또는 이를 포함하는 염증성 장질환 및 자가면역 질환의 예방 또는 치료용 약학 조성물
EP3775908A1 (en) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
EP3801513A1 (en) 2018-05-30 2021-04-14 Machover, David Methods and pharmaceutical compositions for treating cancer
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN112703011A (zh) 2018-08-06 2021-04-23 国家医疗保健研究所 用于治疗癌症的方法和组合物
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3924520A1 (en) 2019-02-13 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
EP3935193A1 (en) 2019-03-06 2022-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to diagnose a cmmrd
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2022538733A (ja) 2019-05-20 2022-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 新規抗ｃｄ２５抗体
US20220290244A1 (en) 2019-08-02 2022-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for screening a subject for a cancer
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
EP4284420A1 (en) 2021-01-29 2023-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to diagnose msi cancer
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN114230514A (zh) * 2021-11-26 2022-03-25 渭南瑞联制药有限责任公司 一种合成3-氟-2-氨基异烟腈的方法
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302591D0 (en) * 1983-01-31 1983-03-02 Fujisawa Pharmaceutical Co Thiazole derivatives
FR2581063B1 (fr) * 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US4876252A (en) 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4788195A (en) 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
JPH0753666B2 (ja) * 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
DE3905763A1 (de) * 1989-02-24 1990-09-06 Bayer Ag Sulfonylierte azinyliminoheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW225528B (et) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1994001423A1 (en) 1992-07-07 1994-01-20 Nippon Soda Co., Ltd. Thiazole derivative
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
JPH07149745A (ja) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
US5530000A (en) * 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
DE69511089T2 (de) 1994-06-22 1999-12-16 British Biotech Pharm Metalloproteinase-inhibitoren
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
DE19824175A1 (de) 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
AU4506399A (en) 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
DE69923681T2 (de) * 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
RU2312860C2 (ru) * 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ

Also Published As

Publication number Publication date
DE60023926T2 (de) 2006-07-20
JP2007045835A (ja) 2007-02-22
ES2250186T3 (es) 2006-04-16
ZA200201898B (en) 2003-05-28
BR0013899A (pt) 2003-07-08
CN1390215A (zh) 2003-01-08
IL148385A0 (en) 2002-09-12
EP1218376A4 (en) 2002-11-20
SK4772002A3 (en) 2002-11-06
AU779908B2 (en) 2005-02-17
HUP0202682A2 (hu) 2003-02-28
JP2003509342A (ja) 2003-03-11
MXPA02002559A (es) 2002-07-30
KR20020027635A (ko) 2002-04-13
US20020147203A1 (en) 2002-10-10
CZ2002861A3 (cs) 2002-06-12
CA2384101A1 (en) 2001-03-15
NO20021166D0 (no) 2002-03-08
NO20021166L (no) 2002-04-25
DE60023926D1 (de) 2005-12-15
ATE309241T1 (de) 2005-11-15
AU7351700A (en) 2001-04-10
PL355639A1 (en) 2004-05-04
US20030064996A1 (en) 2003-04-03
HUP0202682A3 (en) 2003-03-28
EA200200351A1 (ru) 2002-10-31
BG106465A (en) 2002-12-29
WO2001017995A1 (en) 2001-03-15
JP3892296B2 (ja) 2007-03-14
EP1218376A1 (en) 2002-07-03
US6586423B2 (en) 2003-07-01
US6586424B2 (en) 2003-07-01
EP1218376B1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
EE200200123A (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine
YU28602A (sh) Inhibitori tirozin kinaze
EP1226119A4 (en) TYROSIN KINASE INHIBITORS
AU3857501A (en) Tyrosine kinase inhibitors
WO2002045652A3 (en) Tyrosine kinase inhibitors
ATE316088T1 (de) Tyrosin-kinase inhibitoren
EP1503757A4 (en) INHIBITORS OF TYROSINE KINASE
WO2003037252A3 (en) Tyrosine kinase inhibitors
WO2004052315A3 (en) Tyrosine kinase inhibitors
WO2002032861A3 (en) Orally active salts with tyrosine kinase activity
WO2004052286A3 (en) Tyrosine kinase inhibitors
WO2004041164A3 (en) Kinase inhibitors
WO2003088900A3 (en) Solid forms of salts with tyrosine kinase activity
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BRPI0513836A (pt) composto, métodos de tratar, controlar ou prevenir cáncer, uma doença associada com angiogênese indesejada, e uma doença ou distúrbio mediado por pde 4, e de reduzir ou inibir o nìvel ou a atividade de pde 4 em um paciente, e, composição farmacêutica
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
WO2003020699A3 (en) Tyrosine kinase inhibitors
WO2003015717A3 (en) Tyrosine kinase inhibitors
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом